期刊文献+

聚乳酸羟基乙酸-泊洛沙姆纳米微粒作为siRNA载体的可行性 被引量:4

Feasibility of PLGA-poloxamer nanoparticle used as siRNA carrier
原文传递
导出
摘要 目的探讨聚乳酸羟基乙酸-泊洛沙姆(PLGA—Poloxamer)纳米微粒作为siRNA载体的可行性。方法乳剂溶解扩散法制备PLGA—Poloxamer纳米微粒,观察纳米微粒的物理特征,探讨不同制备条件对纳米微粒物理特征的影响,测定其对含siRNA片段的质粒DNA的包裹效率,检测释放的质粒DNA的结构稳定性,验证纳米微粒对质粒DNA的保护作用,测定其作为载体的基因转染效率。结果PLGA—Poloxamer纳米微粒呈球形,粒径约为(210.1±24.3)nm,zeta电位为(-0.43±1.43)mv,包裹效率为31%。该微粒对质粒DNA有保护作用,释放的质粒DNA结构稳定,转染效率达28%。结论PLGA—Poloxamer纳米微粒有望成为较理想的siRNA载体。 Objective To investigate the feasibility of PLGA-poloxamer nanoparticle used as siRNA carrier. Methods Nanoparticle was prepared by solvent diffusion technique. The diameter, zeta potential and superficial appearance of nanoparticles were observed. Entrapment efficiency of plasmid DNA, integrity of plasmid DNA released from nanoparticles, DNA protection effect, and transfection efficiency were examined. Results PLGA-poloxamer was a globular particle with diameter about ( 210.1 ± 24.3 ) nm, zeta potential about ( - 0.43 ±1.43 ) mV, and its entrapment efficiency of plasmid DNA was about 31%. Plasmid DNA released from the nanoparticles was almost kept intact. This nanoparticle could protect plasmid against DNase I digestion and the transfection efficiency was 28%. Conclusion PLGA-poloxamer nanoparticle should be considered as an alternation of siRNA carrier.
出处 《中华实验外科杂志》 CAS CSCD 北大核心 2009年第3期315-317,共3页 Chinese Journal of Experimental Surgery
基金 基金项目:国家自然科学基金资助项目(30500490)
关键词 纳米微粒 RNA干扰 聚乳酸羟基乙酸 泊洛沙姆 Nanoparticle RNA interference polylactic glycolic acid Poloxamer
  • 相关文献

参考文献4

二级参考文献18

  • 1张阳德,翟登高,龚连生,席浩,潘一峰,李浩,刘勤,黄林,吴泽建.半乳糖化白蛋白磁性阿霉素纳米粒制备工艺的优化及缓释性的研究[J].中华实验外科杂志,2004,21(8):1000-1002. 被引量:3
  • 2黄开红,赵晓龙,朱兆华,刘建化,李东印,闵军,陈汝福,常津,刘晓燕.5-氟尿嘧啶聚乳酸载药纳米微粒对人胃癌和结肠癌细胞株的体外杀伤效应[J].中华实验外科杂志,2005,22(5):606-608. 被引量:27
  • 3黄开红,朱兆华,刘建化,陈其奎,刘晓燕,常津.聚乳酸载药纳米微粒制备及其释药效能[J].癌症,2005,24(8):1023-1026. 被引量:25
  • 4Avgoustakis K,Beletsi A,Panagi Z PLGA-mPEG nanoparticles of cisplatin:in vitro nanoparticle degradation,in vitro drug release and in vivo drug residence in blood properties.J Control Release,2002,79:123-135.
  • 5Chen CC,Chueh JY,Tseng H Preparation and characterization of biodegradable PLA polymeric blends.Biomaterials,2003,24:1167-1173.
  • 6Leo E,Brina B,Fomi F In vitro evaluation of PLA nanoparticles containing a lipophilic drug in water-soluble or insoluble form.Int J Pharm,2004,278:133-141.
  • 7Leo E,Cameroni R,Forni F.Dynamic dialysis for the drug release evaluation from doxorubicin-gelatin nanoparticle conjugates.Int J Pharm,1999,180:23-30.
  • 8Leo E,Brina B, Forni F, et al. In vitro evaluation of PLA nanoparticles containing a lipophilic drug in water-soluble or insoluble form. Int J Pharm, 2004,278 : 133-141.
  • 9Kader A,Jalil R. Effect of physicochemical factors on the release kinetics of hydrophilic drugs from poly ( L-lactic acid ) (L-PLA) pellets. Drug Dev Ind Pharm, 1998,24:535-539.
  • 10De Rosa G, Quaglia F,Bochot A, et al. Long-term release and improved intracellular penetration of oligonucleotide-polyethylenimine complexes entrapped in biodegradable microspheres. Biomacromolecules, 2003,4 :529-536.

共引文献16

同被引文献31

  • 1王睿,裴斐,陈迁,方向群,刘又宁.尿激酶或蚓激酶与氟罗沙星联合应用对细菌生物被膜的影响(英文)[J].中国抗生素杂志,2004,29(11):675-678. 被引量:7
  • 2欧元祝,朱于莉,陈洁敏,秦智强,江娟,杨晓梅,瞿涤.表皮葡萄球菌AtlE蛋白介导生物膜起始黏附的相关机制[J].复旦学报(医学版),2006,33(5):569-573. 被引量:9
  • 3任勇亚.RNA干扰抑制MDR1表达并逆转Bel7402/5-Fu肝癌细胞耐药性的研究[J].中南大学学报(医学版),2006,31(6):872-876. 被引量:1
  • 4AAGAARD L, ROSSI J J. RNAi therapeutics: PrinCiples, prospects and challenges [ J ]. Advanced Drug Delivery Reviews ,2007,59 (2): 76-83.
  • 5ACHARYA G,SHIN C S, VEDANTHAM K, et al. A study of drug release from homogeneous PLGA microstructures [ J ]. Journal of Controlled Release,2010,146 (2) :201-206.
  • 6PAN G D, YANG J Q, YAN L N. Reversal of multi-drug resistance by pSUPER-shRNA-mdrl in vivo and in vitro [ J ]. World Journal of Gastroenterol, 2009,15 ( 4 ) :431-440.
  • 7WHITEHEAD K A, LANGER R. Knocking down barriers : advances in siRNA delivery [ J ]. Nature,2009,8 ( 2 ) : 129-138.
  • 8CHEN G, WANG Y, ZHOU M, et al. EphA1 receptor silencing by small interfering RNA has antiangiogenic and antitumor efficacy in hepatocellular carcinoma [ J ]. Oncology Reports, 2010,23 ( 2 ) : 563- 570.
  • 9CHITWOOD'D H ,TIMMERMANS M C. Small RNAs are on the move [J]. Nature,2010,467(7 314) :415-419.
  • 10DINARVAND R, SEPEHRI N, MANOOCHEHRI S, et al. Polylactide-co-glycolide Nanoparticles for controlled delivery of anti cancer agents[ J]. International Journal of Nanomedicine ,2011,6 ( 1 ) : 877- 895.

引证文献4

二级引证文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部